Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
3.29
-0.06 (-1.79%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
3.28
-0.01 (-0.30%)
Bozordan keyin: Aug 12, 2026, 6:50 PM EDT
Recursion Pharmaceuticals, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, AQSh va Buyuk Britaniyada dorilarni kashf qilishni sanoatlashtirish uchun biologiya, kimyo, avtomatlashtirish, ma'lumotlar fanlari va muhandislik bo'yicha texnologik innovatsiyalarni integratsiyalash orqali biologiya va kimyoni dekodlash bilan shug'ullanadi. Kompaniya oilaviy adenomatöz polipozni davolash uchun 1b/2 bosqichdagi klinik sinovda bo'lgan REC-4881; rivojlangan qattiq o'smalarni davolash uchun 1/2 bosqichdagi klinik sinovda bo'lgan REC-617; biomarker-boyitilgan qattiq o'smalar va limfomani davolash uchun 1/2 bosqichdagi klinik sinovda bo'lgan REC-1245; qaytalangan yoki refrakter B-hujayrali malignliklarni davolash uchun 1/2 bosqichida bo'lgan REC-3565; va qattiq o'smalar va gematologik onkologiyani davolash uchun LSD1 ning qaytariladigan, CNSga kiruvchi, og'iz orqali bioavailable va potentsial eng yaxshi sinf inhibitori bo'lgan REC-4539ni ishlab chiqadi. Uning preklinik bosqichdagi mahsulotlari orasida HR+ ko'krak bezi saratonini davolash uchun REC-7735; va gipofosfataziyani davolash uchun REC-102 mavjud. Kompaniya Roche & Genentech; Sanofi; Bayer AG; Tempus; va Takeda Pharmaceutical Company Limited bilan hamkorlik va kelishuvga ega. Recursion Pharmaceuticals, Inc. 2013 yilda tashkil etilgan va shtab-kvartirasi Salt Leyk Siti, Yuta shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David Hallett Ph.D. | Chief Scientific Officer |
| Dr. Najat Khan Ph.D. | CEO, President & Director |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
| Mr. Ben R. Taylor | CFO & President of Recursion UK |
| Mr. Benjamin Mabey M.S. | Chief Technology Officer |
| Mr. Matthew Kinn M.B.A. | Chief Business Officer |
| Mr. Nathan Hatfield J.D., M.B.A. | Chief Legal Officer & Corporate Secretary |
| Mr. Ryan Kelly | Chief Communications Officer |
| Mr. Sid Jain | Senior Vice President of Clinical Development & Data Science |
| Ms. Erica Fox | Chief People and Impact Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-05 | 8-K | rxrx-20260805.htm |
| 2026-06-18 | 8-K | rxrx-20260617.htm |
| 2026-05-06 | 8-K | rxrx-20260506.htm |
| 2026-05-06 | 10-Q | rxrx-20260331.htm |
| 2026-04-30 | DEF 14A | rxrx-20260430.htm |
| 2026-04-30 | 8-K | rxrx-20260428.htm |
| 2026-03-25 | 8-K | rxrx-20260325.htm |
| 2026-02-25 | S-8 | a2026s-8xeipespp.htm |
| 2026-02-25 | 10-K | rxrx-20251231.htm |
| 2026-01-12 | 8-K | rxrx-20260112.htm |